Alpuente, Alicia
Gallardo, Victor J
Caronna, Edoardo
Torres-Ferrus, Marta
Pozo-Rosich, Patricia
Article History
Received: 18 October 2021
Accepted: 29 November 2021
First Online: 13 December 2021
Declarations
:
: The study was approved by the Vall d’Hebron Ethics Committee (PR(AG)53/2017). All patients gave an informed consent for the analysis of patients’ data. All patients consented to publication of anonymous individual data.
: In relation with this paper the authors have nothing to disclose. AA has received honoraria as speaker from Allergan-AbbVie and education from Novartis and Eli Lilly. VJG has nothing to disclose. EC has received honoraria as speaker from Novartis. MT-F has received honoraria as a speaker from Allergan-AbbVie, Chiesi, Eli Lilly and Novartis. In the last 18 months, PP-R has received honoraria as a consultant and speaker from Allergan-AbbVie, Biohaven, Chiesi, Eli Lilly, Medscape, Neurodiem, Novartis and Teva Pharmaceuticals. Her research group has received research grants from Allergan-AbbVie, AGAUR, la Caixa foundation, Migraine Research Foundation, FEDER RISC3CAT, Instituto Investigación Carlos III, MICINN, PERIS; and has received funding for clinical trials from Alder, Allergan-AbbVie, Electrocore, Eli Lilly, Novartis and Teva. She is a trustee member of the board of the International Headache Society and a member of the Council of the European Headache Federation. She is in the editorial board of Revista de Neurologia. She is an associate editor for Cephalalgia, Headache, Frontiers of Neurology and an advisory Scientific member of the Editorial Board of The Journal of Headache and Pain. She is a member of the Clinical Trials Guidelines Committee and Scientific Committee of the International Headache Society. She has edited the Guidelines for the Diagnosis and Treatment of Headache of the Spanish Neurological Society. She is the founder of ExternalRef removed. PP-R does not own stocks from any pharmaceutical company.